Cocrystal Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on July 12, 2021. The company is listed on The Nasdaq Capital Market. The filing serves as a Regulation FD disclosure to make an updated corporate presentation available to the public.
Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The document is a disclosure notice regarding a corporate presentation rather than a financial report.
Material Changes
No material changes to financial performance or operations are reported within the text of this filing. The primary event is the release of an updated corporate presentation dated July 2021.
Guidance, Outlook, and Risks
The filing references an attached corporate presentation (Exhibit 99.1) which likely contains management commentary and outlook, but the text of the 8-K itself does not detail specific guidance, risks, or contingencies. The company explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the contents of the "Cocrystal Pharma, Inc. Corporate Presentation, dated July 2021" (Exhibit 99.1) for actual business updates.
- Note that the presentation is furnished but not "filed" under the Exchange Act, limiting its legal liability status.
- Confirm the company's status as an emerging growth company (unchecked in this filing) and its listing on the Nasdaq Capital Market.
- Review the signature block noting James Martin as Co-Interim Chief Executive Officer and Chief Financial Officer.